Medical Health & Life Science Research News

New study: Cyclin dependent kinase 4 research report

Medical Market Research

Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition.

Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.

Report Source:…e-review-h2-2017


  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4
  • The report reviews Cyclin Dependent Kinase 4 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 4 targeted therapeutics and enlists all their major and minor projects

Report available at:

Companies Mentioned

  • Beta Pharma Inc
  • Eli Lilly and Co
  • G1 Therapeutics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • MEI Pharma Inc
  • Novartis AG
  • Onconova Therapeutics Inc
  • Pfizer Inc
  • Sihuan Pharmaceutical Holdings Group Ltd
  • Teijin Pharma Ltd
  • Tiziana Life Sciences Plc
  • ViroStatics srl

Got a question; ask us at:

News From

The Market Reports - Industry & Market Reports at its BESTThe Market Reports
Category: Market Research Publishers and RetailersCompany about: The Market Reports aims to provide the best industry and market reports to a seeker. We are looking forward to a place where we are the one stop destination for all the report seekers irrespective of any country, category, domain, etc. We are always open on call and email (24*7) to your queries and very clean with the business methodology. Since we are dealing with so many Publishers, we can actually give you what suits best in accordance to your requirements.